Change Healthcare
Get twice-weekly insights on the biggest stories shaping cardiology.
You might also like
Cardiology Pharmaceuticals March 24, 2025
Amvuttra Arrives for ATTR-CM with a High Asking Price March 24, 2025
It’s not surprising that Alnylam’s Amvuttra (vutrisiran) received FDA approval for ATTR-CM last week, but what shocked many was Alnylam’s choice to price the drug at nearly half a million dollars per year in a segment where its incumbent competitors cost half as much. Alnylam claims Amvuttra’s eyewatering price stems from the drug’s “compelling and […]
Structural Heart March 20, 2025
Amulet’s Slight Edge over Watchman 2.5 for LAAO March 20, 2025
Although there’s still ongoing debate on who should receive LAAO devices, new five year results from the Amulet IDE trial confirm that both Abbott’s Amulet occluder and Boston Scientific’s Watchman 2.5 are safe and effective in the long run. Amulet IDE set Abbott’s contender against Boston Scientific’s Watchman 2.5 (its three generation old model), randomizing […]
Cardiology Pharmaceuticals March 17, 2025
Reconsidering LAAO Postprocedural Management March 17, 2025
Real-world data from the EMERGE LAA postapproval study suggests it might be time to rethink the discharge medications prescribed to patients after LAAO. Diving deeper into data from Abbott’s 11.5k patient EMERGE LAA postapproval study, researchers compared the adverse events and six month outcomes of single antiplatelet therapy (5.3% of patients), DAPT (81.7%), and oral […]
